A Phase 1, Two-Part, Open-Label Study to Assess the Relative Bioavailability of Two TD-1473 Tablet Formulations Under Fasted and Fed Conditions in Healthy Subjects and the Pharmacokinetics of TD-1473 in Healthy Chinese Subjects
Latest Information Update: 12 Apr 2021
At a glance
- Drugs Izencitinib (Primary)
- Indications Inflammatory bowel diseases; Intestinal disorders
- Focus Pharmacokinetics
- Sponsors Theravance Biopharma
- 08 Apr 2021 Status changed from recruiting to completed.
- 16 Nov 2020 Status changed from not yet recruiting to recruiting.
- 16 Oct 2020 New trial record